1. To the Editor
================

Loss-of-function mutations in the sphingomyelin phosphodiesterase 1 (*SMPD1*) gene are associated with decreased catalytic activity of acid sphingomyelinase (ASM) and are the cause of the autosomal recessive lysosomal storage disorder Niemann-Pick disease types A and B (NPD). Currently, \>100 missense mutations in *SMPD1* are listed in the Human Gene Mutation Database. However, not every sequence variation in *SMPD1* is detrimental and gives rise to NPD.

In order to identify mutations in the *SMPD1* gene that potentially explain increased ASM activity associated with major depressive disorder \[[@B1-ijms-16-13649]\] we performed a re-sequencing analysis of the six exons of *SMPD1*. This region includes a 1896 bp open reading frame that encodes a 631 amino acid protein according to NCBI Reference Sequence NM_000543.4. We identified three non-synonymous single nucleotide polymorphisms (SNP)-c.973C\>G (p.P325A), c.1460C\>T (p.A487V) and c.1522G\>A (p.G508R; rs1050239)-as well as a bipartite polymorphic site including the non-synonymous SNP c.107T\>C (p.V36A; rs1050228), which is located adjacent to a polymorphic region composed of a variable number of hexanucleotide sequences. Two of these variants, p.P325A and p.A487V, were previously reported to constitute loss-of-function mutations of *SMPD1* \[[@B2-ijms-16-13649]\], whereas the other two, p.G508R and the hexanucleotide repeat, an association with NPD was ruled out \[[@B3-ijms-16-13649],[@B4-ijms-16-13649]\]. To analyze the functional implications of these polymorphisms in detail, we first conducted genotype-phenotype correlations in different human samples (e.g., a comparison of individual *SMPD1* genotypes with the respective *in vivo* ASM activities) and, second, cloned the respective cDNAs for transient transfection studies. Hereby, we were able to demonstrate that the carriers of c.1460C\>T (minor allele frequency \~1%) displayed secreted (S-) and lysosomal (L-) ASM activities in the normal range \[[@B5-ijms-16-13649]\]. Moreover, transient transfection of c.1460T-cDNA into HeLa and MDCK cells resulted in S- and L-ASM activities similar to wild-type ASM \[[@B5-ijms-16-13649]\]. The genotype-phenotype comparison for c.1522G\>A (minor allele frequency \~27%), on the other hand, revealed a significant association especially with the S-ASM activity, which decreased with the number of A alleles in a gene-dosage dependent manner \[[@B6-ijms-16-13649]\]. S-ASM activity in subjects homozygous for c.1522G\>A was 50% decreased compared to subjects homozygous for the major allele c.1522G \[[@B6-ijms-16-13649]\]. In sharp contrast, NPD patients and carriers of NPD alleles were reported to display S-ASM activities \<3% and about 20% of normal values, respectively \[[@B7-ijms-16-13649]\]. Thus, the only moderately decreased S-ASM activity in subjects homozygous for c.1522A and the high allele frequency argue strongly against the notion that c.1522G\>A constitutes a loss-of-function mutation causing NPD. In addition, a transient transfection of a c.1522A-construct into HeLa and MCDK cells resulted in L- and S-ASM activities comparable to wild-type ASM ([Figure 1](#ijms-16-13649-f001){ref-type="fig"}). The functional relevance of c.107T\>C was analyzed together with that of the adjacent polymorphic hexanucleotide repeat. While we obtained data showing that less repeats of the hexanucleotide motif are associated with slightly decreased S-ASM activity *in vivo* and *in vitro* \[[@B8-ijms-16-13649]\], we did not observe a significant reduction of ASM activity associated with c.107T\>C, neither *in vivo* nor *in vitro* ([Figure 1](#ijms-16-13649-f001){ref-type="fig"}). In contrast, transient transfection of a c.973G-construct into HeLa and MDCK cells did not increase ASM activity compared to control cells, thus confirming that c.973C\>G is a NPD mutation ([Figure 1](#ijms-16-13649-f001){ref-type="fig"}).

![Analysis of sphingomyelin phosphodiesterase 1 (*SMPD1*) sequence variations by transient transfection studies. The full-length *SMPD1* cDNA was cloned into the FLAG-N2 expression vector, and the *SMPD1* variants p.V36A, p.P325A, p.A487V and p.G508R were generated by site-directed mutagenesis. The variant cDNAs and the empty FLAG-N2 vector (mock) were transiently transfected into MDCK cells, and acid sphingomyelinase activity was determined from cell lysates (L-ASM activity; **upper** panel) and supernatants (S-ASM activity; **lower** panel). Representative results of a typical experiment with three replicates are given as fold increase over the mock-transfected control. Error bars indicate the standard deviation. With the exception of p.P325A, all mutants increased acid sphingomyelinase activity by \>fivefold, similarly to *SMPD1* wild-type. Methods are described in detail in \[[@B5-ijms-16-13649]\].](ijms-16-13649-g001){#ijms-16-13649-f001}

2. Conclusions
==============

Our results strongly support the notion that p.V36A, p.A487V and p.G508R are frequent polymorphisms in *SMPD1*. These polymorphisms might increase the susceptibility for common diseases such as allergy \[[@B6-ijms-16-13649]\], but they do not constitute loss-of-function mutations that are responsible for the occurrence of NPD. Since the alleged loss-of function mutations in 12 out of 15 NPD patients reported by Manshadi *et al.* \[[@B9-ijms-16-13649]\] are common polymorphisms, a critical molecular, biochemical and clinical evaluation of the mentioned patients is recommended.
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